Recombinant Mouse PD-1 protein (His Tag)

种属

Mouse

纯度

>90 %, SDS-PAGE

标签

His Tag

生物活性

未测试

Cat no : Eg0918

Print datasheet

Synonyms

CD279, PD1, PD 1, Pdc1, Pdcd1



产品信息

纯度 >90 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性
Not tested
来源 HEK293-derived Mouse PD-1 protein Leu25-Gln167 (Accession# Q02242) with a His tag at the C-terminus.
基因ID 18566
蛋白编号 Q02242
预测分子量 17.2 kDa
SDS-PAGE 35-45 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

Programmed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acids type I transmembrane protein composed of a Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM), as well as an immunoreceptor tyrosine-based switch motif (ITSM). PD-1 can be expressed on activated T cells, B cells, natural killer T cells, monocytes, and dendritic cells (DCs). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function. It is critical for the regulation of T cell function during tolerance, autoimmunity and infection. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity.

参考文献:

1. Arlene H Sharpe, et al. (2007) Nat Immunol. 8(3):239-45. 2. Mary E Keir, et al. (2008) Annu Rev Immunol. 26:677-704. 3. James L Riley. (2009) Immunol Rev. 229(1):114-25. 4. Loise M Francisco, et al. (2010) Immunol Rev. 236:219-42. 5. Suzanne L Topalian, et al. (2012) N Engl J Med. 366(26):2443-54.